Search Results - "Llombart, A."

Statistical Analysis of Wind Power Forecast Error by Bludszuweit, H., Dominguez-Navarro, J.A., Llombart, A.

“…Wind power forecast error usually has been assumed to have a near Gaussian distribution. With a simple statistical analysis, it can be shown that this is not…”
Get full text

Optimal Design of ICPT Systems Applied to Electric Vehicle Battery Charge by Sallan, J., Villa, J.L., Llombart, A., Sanz, J.F.

“…Although the use of inductively coupled power transfer (ICPT) systems for electric vehicle battery charge presents numerous advantages, a detailed design…”
Get full text

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results by Coleman, R., de Boer, R., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., von Minckwitz, G., Sleeboom, H.P., Forbes, J., Barrios, C., Frassoldati, A., Campbell, I., Paija, O., Martin, N., Modi, A., Bundred, N.

“…Aromatase inhibitors are the preferred adjuvant endocrine therapy for the majority of postmenopausal women with hormone-responsive early breast cancer…”
Get full text

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group by Gronchi, A., Stacchiotti, S., Verderio, P., Ferrari, S., Martin Broto, J., Lopez-Pousa, A., Llombart-Bosch, A., Dei Tos, A.P., Collini, P., Jurado, J.C.r.u.z., De Paoli, A., Donati, D.M., Poveda, A., Quagliuolo, V., Comandone, A., Grignani, G., Morosi, C., Messina, A., De Sanctis, R., Bottelli, S., Palassini, E., Casali, P.G., Picci, P.i.e.r.o.

“…The equivalence of a short full-dose regimen of neoadjuvant CT with anthracycline-ifosfamide compared with standard dosing in localized high-risk soft tissue…”
Get full text

Robust filtering for the characterization of wind turbines: Improving its operation and maintenance by Sainz, E., Llombart, A., Guerrero, J.J.

“…The need to obtain automatic filters to treat wind data is clear due to the huge amount of data available in any wind farm analysis. Automatic detection of…”
Get full text

Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life by Fernández-Ortega, P., Caloto, M. T., Chirveches, E., Marquilles, R., Francisco, J. San, Quesada, A., Suárez, C., Zorrilla, I., Gómez, J., Zabaleta, P., Nocea, G., Llombart-Cussac, A.

“…Background Chemotherapy-induced nausea and vomiting (CINV) in cancer patients are common symptoms most feared by patients. The aim of this study was to analyze…”
Get full text

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy by Marty, M., Espié, M., Llombart, A., Monnier, A., Rapoport, B.L., Stahalova, V.

“…Background: Anthracycline-induced cardiotoxicity has led to the adoption of empirical dose limits that may restrict continued use of anthracyclines among…”
Get full text

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer by Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V.F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R.H., Matera, J., Azarnia, N., Hudis, C.A., Rozencweig, M.

“…Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet®) in combination…”
Get full text

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer by Baselga, J, Manikhas, A, Cortés, J, Llombart, A, Roman, L, Semiglazov, V F, Byakhov, M, Lokanatha, D, Forenza, S, Goldfarb, R H, Matera, J, Azarnia, N, Hudis, C A, Rozencweig, M

Get full text

Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers by Llombart, B, Monteagudo, C, López-Guerrero, J A, Carda, C, Jorda, E, Sanmartín, O, Almenar, S, Molina, I, Martín, J M, Llombart-Bosch, A

“…Aims:  To evaluate the clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma (MCC) in an attempt to find new, potentially…”
Get full text

Impact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: Results of the KARMA Dx study by Llombart, A., Andrés, R., Anton Torres, A., Martinez, N., Rodriguez, C., Sánchez-Rovira, P., Rojas, B., Ruiz Borrego, M., Bermejo, B., Martinez de Dueñas, E.

Get full text

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study by Gil-Gil, Miguel J., Bellet, M., Morales, S., Ojeda, B., Manso, L., Mesia, C., Garcia-Martínez, E., Martinez-Jáñez, N., Melé, M., Llombart, A., Pernas, S., Villagrasa, P., Blasco, C., Baselga, J.

“…Anthracycline and taxane-based primary chemotherapy (PCT) is the standard treatment for high-risk breast cancer (HRBC). However, conventional anthracyclines…”
Get full text

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial by Gligorov, J., Pivot, X., Ataseven, B., De Laurentiis, M., Llombart, A., Jung, K.H., Manikhas, A., Azim, H.A., Alexandrou, A., Gupta, K., Herraez-Baranda, L., Tosti, N., Restuccia, E.

Get full text

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis by Cortes, J, Calvo, V, Ramírez-Merino, N, O'Shaughnessy, J, Brufsky, A, Robert, N, Vidal, M, Muñoz, E, Perez, J, Dawood, S, Saura, C, Di Cosimo, S, González-Martín, A, Bellet, M, Silva, O E, Miles, D, Llombart, A, Baselga, J

Get full text

Corrections to “Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis” by Cortes, J., Calvo, V., Ramírez-Merino, N., O'Shaughnessy, J., Brufsky, A., Robert, N., Vidal, M., Muñoz, E., Perez, J., Dawood, S., Saura, C., Di Cosimo, S., González-Martín, A., Bellet, M., Silva, O.E., Miles, D., Llombart, A., Baselga, J.

Get full text

Progression of follicular lymphoma grade I in the central nervous system by Cózar Santiago, M.P., Cánoves Llombart, A., Sanz Llorens, R., Soler López, M., Escrivá Torres, A., Ferrer Rebolleda, J.

Get full text

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis by Cortes, J., Calvo, V., Ramírez-Merino, N., O'Shaughnessy, J., Brufsky, A., Robert, N., Vidal, M., Muñoz, E., Perez, J., Dawood, S., Saura, C., Di Cosimo, S., González-Martín, A., Bellet, M., Silva, O.E., Miles, D., Llombart, A., Baselga, J.

“…Bevacizumab is a monoclonal antibody against vascular endothelial growth factor with the ability to increase progression-free survival in metastatic breast…”
Get full text

CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors by Monteagudo, C, Martin, J M, Jorda, E, Llombart-Bosch, A

“…Background: A role for CXCR3, the receptor for chemokines Mig, IP-10 and interferon-inducible T cell α-chemoattractant, in tumour cell migration during…”
Get full text

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer by Griguolo, G., Serna, G., Pascual, T., Fasani, R., Guardia, X., Chic, N., Paré, L., Pernas, S., Muñoz, M., Oliveira, M., Vidal, M., Llombart-Cussac, A., Cortés, J., Galván, P., Bermejo, B., Martínez, N., López, R., Morales, S., Garau, I., Manso, L., Alarcón, J., Martínez, E., Villagrasa, P., Prat, A., Nuciforo, P.

“…Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within…”
Get full text

Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study) by Pernas, S., Villagrasa, P., Vivancos, A., Scaltriti, M., Rodon, J., Burgues, O., Nuciforo, P.G., Canes, J., Dueñas, M., Vidal, M., Lluch, A., Perelló, A., Llombart, A., Dorca, J., Montaño, Á, Oliveira, M., Ribas, G., Rapado, I., Prat, A., Ciruelos, E.M.

Get full text